PROCEPT BioRobotics Corporation (PRCT)

NEUTRAL

HealthcareMedical DevicesUnited States

基本面

价格

$21.24

市值

$1.20B

Yahoo Finance TradingView 新闻官网

第一部分 · 这家公司值多少

概览

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$337M

最近12个月（截至2026/6/30）

净利润

$-110M

最近12个月（截至2026/6/30）

自由现金流

$-58M

股东权益合计

$366M

负债合计

$142M

流动比率

6.55

利息覆盖率

32.88

债务/EBITDA

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

General case合理估值

公允价值

$21.64

当前价格

$21.24

安全边际

+1.8%

公允价值区间

$20.55 - $22.72

估算方法

Analyst price target:$21.64

Discounted cash flow (DCF):Not enough data to compute it

Earnings multiple (P/E):Not enough data to compute it

Graham growth formula:Not enough data to compute it

Earnings power value (EPV):Not enough data to compute it

Justified P/B:Not enough data to compute it

Dividend discount (Gordon):Not enough data to compute it

P/FFO, funds from operations:Not enough data to compute it

Mid-cycle earnings:Not enough data to compute it

Revenue multiple:$22.12

分析师共识:买入 (12B / 8H / 1S)

最近财报超预期:-0.84%

估值指标

市盈率（P/E）

ROE

-26.1%

市净率（P/B）

3.64

P/FCF

毛利率

64.2%

ROIC

-21.7%

盈利能力雷达图

Value Creation (Economic Moat)

ROIC

-21.7%

WACC

9.3%

ROIC − WACC

-31.0 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

基本面分析标准

通过（8）

EPS shows upward trend
Gross Margin 64.2%
Debt/Equity ratio
Current Ratio
Interest Coverage
Low reliance on intangibles
Revenue Growth 5Y 109.0%
Analyst Consensus 57% Buy

未通过（12）

Price CAGR -2.82%
ROIC -21.7%
P/B Ratio 3.64
Operating Margin -33.9%
Positive Free Cash Flow
Return on Tangible Assets
DCF valuation (Unknown)
ROE -30.6%
Earnings Surprise avg -12.6%
Share Dilution 6.4%
Net Margin Trend -32.5% vs -30.6%
Piotroski F-Score 3/9

不可用（7）

P/FCF NaN
Dividend Payout NaN%
CapEx intensity
Debt/EBITDA
Price below Graham Number
PEG Ratio (need PE > 0 and growth > 0)
Earnings Quality (OCF/Net Income)

Piotroski F-评分

3/9

存在严重财务隐患

score

criteria

盈利质量

低质量：需深入审查会计处理

股权稀释

6.4%

正在发行新股，稀释所有权

公司治理

管理团队

姓名	职位	年龄
Mr. Larry L. Wood	President, CEO & Director	59
Mr. Kevin Waters	Executive VP & CFO	48
Ms. Alaleh Nouri	EVP, Chief Legal Officer & Corporate Secretary	46
Mr. Christofer Christoforou	Executive Vice President of Operations	55
Mr. Barry Templin	Executive VP & CTO	-
Mr. Matthew James Bacso C.F.A.	Vice President of Investor Relations	-
Ms. Pooja Sharma Rao	Executive VP and Chief Strategy & Marketing Officer	-
Ms. Stacey L. Porter	Executive VP & Chief People Officer	50
Mr. Bijesh Chandran	Executive Vice President of Regulatory Affairs & Quality Assurance	-
Mr. Stephen J. McGill	Senior VP & GM of International	63

审计风险

董事会风险

薪酬风险

股东权利风险

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。

Latest News

Recent headlines for PRCT, sourced from Markets Gazette.

No recent news for PRCT.